Optimizing Intrahepatic Cholangiocarcinoma Staging
CLINICAL NUCLEAR MEDICINE, vol.51, no.8, 2026 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 51 Issue: 8
- Publication Date: 2026
- Doi Number: 10.1097/rlu.0000000000006310
- Journal Name: CLINICAL NUCLEAR MEDICINE
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Istanbul University Affiliated: Yes
Abstract
Herein, we present a case of a patient with intrahepatic cholangiocarcinoma (ICC) who underwent [18F]FDG, [68Ga]Ga-Trivehexin, and [68Ga]Ga-FAPI-04 PET/CT scans for initial staging. The primary liver lesion demonstrates progressively increased uptake across all 3 tracers, whereas metastatic cervical lymph nodes are visualized with [68Ga]Ga-FAPI-04 PET/CT and [68Ga]Ga-Trivehexin but not with [18F]FDG; importantly, [68Ga]Ga-FAPI-04 PET/CT, in addition, delineates metastatic abdominal lymph nodes. This case highlights that [68Ga]Ga-Trivehexin PET/CT may serve as an alternative to [18F]FDG PET/CT, warranting reevaluation of FDG limitations, while FAPI remains a strong competitor to both.